Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H1 2018

Publisher Name :
Date: 27-Feb-2018
No. of pages: 70

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline Target constitutes close to 19 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The latest report Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H1 2018, outlays comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferon-alpha/beta receptor alpha chain. It plays an import role in inflammation. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 9 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Gastrointestinal, Oncology, Central Nervous System, Dermatology, Musculoskeletal Disorders and Undisclosed which include indications Ulcerative Colitis, Psoriasis, Autoimmune Disorders, Inflammation, Inflammatory Bowel Disease, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Crohn's Disease (Regional Enteritis), Multiple Sclerosis, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Alopecia, Arthritis, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Hypersensitivity, Lupus Erythematosus, Lupus Nephritis, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Systemic Lupus Erythematosus, T-Cell Leukemia, Unspecified and Waldenstrom Macroglobulinemia.

Furthermore, this report also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note : Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)

  • The report reviews Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H1 2018

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Overview
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Array BioPharma Inc
Bristol-Myers Squibb Co
Nimbus Therapeutics LLC
Pfizer Inc
Portola Pharmaceuticals Inc
Sareum Holdings Plc
Takeda Pharmaceutical Co Ltd
Theravance Biopharma Inc
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drug Profiles
ARRY-624 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986165 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cerdulatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDI-031232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDI-031301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDI-031407 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OST-122 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OST-246 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06700841 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-20347 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SART-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SART-29 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SART-33 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TYK2 for Autoimmune Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit TYK2 for Ulcerative Colitis and Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit TYK2 for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit Tyrosine Kinase 2 for Inflammatory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-1473 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-3504 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Dormant Products
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Discontinued Products
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Dec 19, 2017: Patent Grants in Japan and China for Sareum's TYK2 Inhibitors
Dec 19, 2017: Sareum announces the Patent Grants in Japan and China for Sareum's TYK2 Inhibitors
Nov 30, 2017: Portola Pharmaceuticals to Present New Data on Cerdulatinib at the 59th American Society of Hematology (ASH) Annual Meeting
Aug 08, 2017: Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis
Jun 23, 2017: European Hematology Association: Two is better than one: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study for Relapsed/Refractory NHL
Jun 15, 2017: Portola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma
Jun 14, 2017: Bristol-Myers Squibb To Present on BMS-986165 at the Annual European Congress of Rheumatology (EULAR 2017)
May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association
May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma
Feb 17, 2017: Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
Feb 13, 2017: Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
Nov 29, 2016: Sareum to Present TYK2 Cancer Research Programme at the 2016 AACR-NCI-EORTC International Conference
Nov 28, 2016: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition
Oct 24, 2016: Sareum Holdings: Successful Outcome from TYK2 Feasibility Study
Oct 04, 2016: Theravance Biopharma Announces First Subject Dosed in Phase 1b Clinical Trial of TD-1473 in Patients With Moderate to Severe Ulcerative Colitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Array BioPharma Inc, H1 2018
Pipeline by Bristol-Myers Squibb Co, H1 2018
Pipeline by Nimbus Therapeutics LLC, H1 2018
Pipeline by Pfizer Inc, H1 2018
Pipeline by Portola Pharmaceuticals Inc, H1 2018
Pipeline by Sareum Holdings Plc, H1 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Pipeline by Theravance Biopharma Inc, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Carbohydrase Market Insights, Forecast to 2025
    Published: 21-Jan-2019        Price: US 3900 Onwards        Pages: 117
    Carbohydrase is a set of enzymes that catalyzes the breakdown of carbohydrates into simple sugars. The increasing use of detergents in industrial and household application is expected to be the dominant factor of the growth of carbohydrase market in future. Global Carbohydrase market size will increase to xx Million US$ by 2025, from xx Million US$ in 2018, at a CAGR of xx% during the forecast period. In this study, 2018 has been considered as the base year and 2019 to 2025 as the ......
  • GALNT2 Market Insights 2019, Global and Chinese Scenario
    Published: 21-Jan-2019        Price: US 3000 Onwards        Pages: 144
    GALNT2 Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global GALNT2 industry with a focus on the Chinese market. The report provides key statistics on the market status of the GALNT2 manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-2024 global and Chinese GALNT2 market covering all important paramete......
  • Global Glucose Oxidase Market Research Report 2019
    Published: 21-Jan-2019        Price: US 2900 Onwards        Pages: 93
    The global Glucose Oxidase market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. This report focuses on Glucose Oxidase volume and value at global level, regional level and company level. From a global perspective, this report represents overall Glucose Oxidase market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Eu......
  • Global Lipase Market Insights, Forecast to 2025
    Published: 16-Jan-2019        Price: US 3900 Onwards        Pages: 119
    Lipase is one of the important industrial enzyme preparations, which can catalyze and dissolve lipid, ester exchange, ester synthesis and other reactions. Consumers are becoming increasingly aware about the health benefits of lipase, which has increased the demand of lipase-based products. Furthermore, factors such as changing dietary patterns, increasing meat and milk consumption, and rising processed food industry are also driving the global lipase market. The global Lipase marke......
  • Viral RNA Polymerase Inhibitor - Pipeline Insight, 2019
    Published: 15-Jan-2019        Price: US 1250 Onwards        Pages: 60
    "Viral RNA Polymerase Inhibitor - Pipeline Insight, 2019" report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across "Viral RNA Polymerase Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.......
  • Xanthine Oxidase Inhibitor - Pipeline Insight, 2019
    Published: 15-Jan-2019        Price: US 1250 Onwards        Pages: 60
    "Xanthine Oxidase Inhibitor - Pipeline Insight, 2019" report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across "Xanthine Oxidase Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. ......
  • Diglyceride Acyltransferase (DGAT) Inhibitor - Pipeline Insight, 2019
    Published: 15-Jan-2019        Price: US 1250 Onwards        Pages: 60
    "Diglyceride Acyltransferase (DGAT) Inhibitor - Pipeline Insight, 2019" report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across "Diglyceride Acyltransferase (DGAT) Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of admini......
  • Dihydroorotate Dehydrogenase (DHODH) Inhibitor - Pipeline Insight, 2019
    Published: 15-Jan-2019        Price: US 1250 Onwards        Pages: 60
    "Dihydroorotate Dehydrogenase (DHODH) Inhibitor - Pipeline Insight, 2019" report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across "Dihydroorotate Dehydrogenase (DHODH) Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of ad......
  • DNA Methyltransferase Inhibitor - Pipeline Insight, 2019
    Published: 15-Jan-2019        Price: US 1250 Onwards        Pages: 60
    "DNA Methyltransferase Inhibitor - Pipeline Insight, 2019" report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across "DNA Methyltransferase Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs